| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | PRL-3 Inhibitor I | CTRPv2 | pan-cancer | AAC | 0.09 | 0.02 |
| mRNA | SU11274 | CTRPv2 | pan-cancer | AAC | 0.083 | 0.02 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.079 | 0.02 |
| mRNA | NSC23766 | CTRPv2 | pan-cancer | AAC | 0.08 | 0.02 |
| mRNA | MGCD-265 | CTRPv2 | pan-cancer | AAC | 0.079 | 0.03 |
| mRNA | BRD-K92856060 | CTRPv2 | pan-cancer | AAC | 0.082 | 0.03 |
| mRNA | Nilotinib | CTRPv2 | pan-cancer | AAC | -0.084 | 0.03 |
| mRNA | MG-132 | CTRPv2 | pan-cancer | AAC | 0.14 | 0.03 |
| mRNA | dacarbazine | CTRPv2 | pan-cancer | AAC | -0.071 | 0.03 |
| mRNA | BRD-K71781559 | CTRPv2 | pan-cancer | AAC | 0.086 | 0.03 |